Zolpidem sublingual - Orexo
Alternative Names: Edluar; OX-22; SublinoxLatest Information Update: 02 Oct 2021
At a glance
- Originator Orexo
- Developer Meda
- Class Acetamides; Hypnosedatives; Imidazoles; Pyridines; Sleep disorder therapies; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Insomnia
Most Recent Events
- 08 May 2019 Launched for Insomnia in Poland, prior May 2019 (Sublingual)
- 30 Apr 2019 The FDA recommends to update the label of zolpidem sublingual (Edluar™) for Insomnia to include Black Box warning regarding the complex sleep behaviors
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies